BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetics of oxatomide given percutaneously to healthy volunteers. 1992

C Benvenuti, and M Broggini, and V Botta, and M Valenti, and G Broccali, and L Dal Bo
Medical Department, Puropharma, Milan-Italy.

The percutaneous absorption of oxatomide gel at 5 per cent concentration was studied after single and repeated administration (85 mg b.i.d.) in six male and six female healthy volunteers, aged 25.7 +/- 0.8 years (mean +/- SEM) weighing 64.4 +/- 4.5 kg and the results compared with those obtained following a single oral dose (30 mg). The measurement of oxatomide was by means of a new sensitive and specific HPLC assay with limits of detection of 0.2 ng ml-1 in plasma and 1.0 ng ml-1 in urine. Poor percutaneous absorption was confirmed by the peak plasma concentrations which were 5.03 +/- 0.79 ng ml-1 following application of the gel for 7 days and 10.08 +/- 1.29 ng ml-1 following oral administration; the corresponding amounts of unchanged oxatomide recovered from 24 h urine collections were 1.42 +/- 0.39 micrograms and 3.93 +/- 0.92 micrograms.

UI MeSH Term Description Entries
D008297 Male Males
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D012015 Reference Standards A basis of value established for the measure of quantity, weight, extent or quality, e.g. weight standards, standard solutions, methods, techniques, and procedures used in diagnosis and therapy. Standard Preparations,Standards, Reference,Preparations, Standard,Standardization,Standards,Preparation, Standard,Reference Standard,Standard Preparation,Standard, Reference
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D005782 Gels Colloids with a solid continuous phase and liquid as the dispersed phase; gels may be unstable when, due to temperature or other cause, the solid phase liquefies; the resulting colloid is called a sol.
D006634 Histamine H1 Antagonists Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. Antihistamines, Classical,Antihistaminics, Classical,Antihistaminics, H1,Histamine H1 Antagonist,Histamine H1 Receptor Antagonist,Histamine H1 Receptor Antagonists,Histamine H1 Receptor Blockaders,Antagonists, Histamine H1,Antagonists, Histamine H1 Receptor,Antihistamines, Sedating,Blockaders, Histamine H1 Receptor,First Generation H1 Antagonists,H1 Receptor Blockaders,Histamine H1 Blockers,Receptor Blockaders, H1,Antagonist, Histamine H1,Classical Antihistamines,Classical Antihistaminics,H1 Antagonist, Histamine,H1 Antagonists, Histamine,H1 Antihistaminics,Sedating Antihistamines
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000279 Administration, Cutaneous The application of suitable drug dosage forms to the skin for either local or systemic effects. Cutaneous Drug Administration,Dermal Drug Administration,Drug Administration, Dermal,Percutaneous Administration,Skin Drug Administration,Transcutaneous Administration,Transdermal Administration,Administration, Dermal,Administration, Transcutaneous,Administration, Transdermal,Cutaneous Administration,Cutaneous Administration, Drug,Dermal Administration,Drug Administration, Cutaneous,Skin Administration, Drug,Administration, Cutaneous Drug,Administration, Dermal Drug,Administration, Percutaneous,Administrations, Cutaneous,Administrations, Cutaneous Drug,Administrations, Dermal,Administrations, Dermal Drug,Administrations, Percutaneous,Administrations, Transcutaneous,Administrations, Transdermal,Cutaneous Administrations,Cutaneous Administrations, Drug,Cutaneous Drug Administrations,Dermal Administrations,Dermal Drug Administrations,Drug Administrations, Cutaneous,Drug Administrations, Dermal,Drug Skin Administrations,Percutaneous Administrations,Skin Administrations, Drug,Skin Drug Administrations,Transcutaneous Administrations,Transdermal Administrations
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

C Benvenuti, and M Broggini, and V Botta, and M Valenti, and G Broccali, and L Dal Bo
Pharmacokinetics of R(+)-terodiline given intravenously and orally to healthy volunteers.
September 1993, Pharmacology & toxicology,
C Benvenuti, and M Broggini, and V Botta, and M Valenti, and G Broccali, and L Dal Bo
Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses.
November 1996, Antimicrobial agents and chemotherapy,
C Benvenuti, and M Broggini, and V Botta, and M Valenti, and G Broccali, and L Dal Bo
Pharmacokinetics of cefroxadine after infusion to healthy volunteers.
October 1990, International journal of clinical pharmacology, therapy, and toxicology,
C Benvenuti, and M Broggini, and V Botta, and M Valenti, and G Broccali, and L Dal Bo
Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers.
January 2011, European journal of clinical pharmacology,
C Benvenuti, and M Broggini, and V Botta, and M Valenti, and G Broccali, and L Dal Bo
Amlodipine pharmacokinetics in healthy volunteers.
November 1988, Journal of clinical pharmacology,
C Benvenuti, and M Broggini, and V Botta, and M Valenti, and G Broccali, and L Dal Bo
Pharmacokinetics of pelanserin in healthy volunteers.
January 1992, Proceedings of the Western Pharmacology Society,
C Benvenuti, and M Broggini, and V Botta, and M Valenti, and G Broccali, and L Dal Bo
[Pharmacokinetics of chlormezanone in healthy volunteers].
January 1990, Therapie,
C Benvenuti, and M Broggini, and V Botta, and M Valenti, and G Broccali, and L Dal Bo
Pharmacokinetics of oxypolygelatine in healthy volunteers.
March 1999, European journal of clinical pharmacology,
C Benvenuti, and M Broggini, and V Botta, and M Valenti, and G Broccali, and L Dal Bo
[Pharmacokinetics of fudosteine in healthy volunteers].
October 2005, Yao xue xue bao = Acta pharmaceutica Sinica,
C Benvenuti, and M Broggini, and V Botta, and M Valenti, and G Broccali, and L Dal Bo
Pharmacokinetics of imipenem in healthy volunteers.
December 1983, The Journal of antimicrobial chemotherapy,
Copied contents to your clipboard!